Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies.

Fujimoto T, Andoh T, Sudo T, Fujita I, Imabori M, Moritake H, Sugimoto T, Sakuma Y, Takeuchi T, Sonobe H, Epstein AL, Akisue T, Kirihata M, Kurosaka M, Fukumori Y, Ichikawa H.

Appl Radiat Isot. 2011 Dec;69(12):1713-6. doi: 10.1016/j.apradiso.2011.02.006. Epub 2011 Feb 12.

PMID:
21354804
2.

Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models.

Andoh T, Fujimoto T, Sudo T, Fujita I, Imabori M, Moritake H, Sugimoto T, Sakuma Y, Takeuchi T, Kawabata S, Kirihata M, Akisue T, Yayama K, Kurosaka M, Miyatake S, Fukumori Y, Ichikawa H.

Appl Radiat Isot. 2011 Dec;69(12):1721-4. doi: 10.1016/j.apradiso.2011.02.005. Epub 2011 Mar 1.

PMID:
21367607
3.

Boron neutron capture therapy as new treatment for clear cell sarcoma: trial on different animal model.

Andoh T, Fujimoto T, Sudo T, Suzuki M, Sakurai Y, Sakuma T, Moritake H, Sugimoto T, Takeuchi T, Sonobe H, Epstein AL, Fukumori Y, Ono K, Ichikawa H.

Appl Radiat Isot. 2014 Jun;88:59-63. doi: 10.1016/j.apradiso.2013.12.007. Epub 2013 Dec 17.

PMID:
24389062
4.

Boron neutron capture therapy (BNCT) as a new approach for clear cell sarcoma (CCS) treatment: Trial using a lung metastasis model of CCS.

Andoh T, Fujimoto T, Suzuki M, Sudo T, Sakurai Y, Tanaka H, Fujita I, Fukase N, Moritake H, Sugimoto T, Sakuma T, Sasai H, Kawamoto T, Kirihata M, Fukumori Y, Akisue T, Ono K, Ichikawa H.

Appl Radiat Isot. 2015 Dec;106:195-201. doi: 10.1016/j.apradiso.2015.07.060. Epub 2015 Aug 21.

PMID:
26337135
5.

Biodistribution of boron compounds in an animal model of human undifferentiated thyroid cancer for boron neutron capture therapy.

Dagrosa MA, Viaggi M, Rebagliati RJ, Batistoni D, Kahl SB, Juvenal GJ, Pisarev MA.

Mol Pharm. 2005 Mar-Apr;2(2):151-6.

PMID:
15804189
6.

Suitability of boron carriers for BNCT: accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA.

Chou FI, Chung HP, Liu HM, Chi CW, Lui WY.

Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S105-8. doi: 10.1016/j.apradiso.2009.03.025. Epub 2009 Mar 26.

PMID:
19375330
7.

In vitro and in vivo evaluation of o-carboranylalanine as a potential boron delivery agent for neutron capture therapy.

Yong JH, Barth RF, Wyzlic IM, Soloway AH, Rotaru JH.

Anticancer Res. 1995 Sep-Oct;15(5B):2033-8.

PMID:
8572598
8.

L-DOPA preloading increases the uptake of borophenylalanine in C6 glioma rat model: a new strategy to improve BNCT efficacy.

Capuani S, Gili T, Bozzali M, Russo S, Porcari P, Cametti C, D'Amore E, Colasanti M, Venturini G, Maraviglia B, Lazzarino G, Pastore FS.

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):562-7. doi: 10.1016/j.ijrobp.2008.06.1493.

PMID:
18793958
9.

Delivery of (10)boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy.

Obayashi S, Kato I, Ono K, Masunaga S, Suzuki M, Nagata K, Sakurai Y, Yura Y.

Oral Oncol. 2004 May;40(5):474-82.

PMID:
15006618
10.

Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model.

Wang HE, Liao AH, Deng WP, Chang PF, Chen JC, Chen FD, Liu RS, Lee JS, Hwang JJ.

J Nucl Med. 2004 Feb;45(2):302-8.

11.

Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy.

Ferrari C, Zonta C, Cansolino L, Clerici AM, Gaspari A, Altieri S, Bortolussi S, Stella S, Bruschi P, Dionigi P, Zonta A.

Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S341-4. doi: 10.1016/j.apradiso.2009.03.059. Epub 2009 Mar 27.

PMID:
19394838
12.

Hydroxylforms of p-boronophenylalanine as potential boron carriers on boron neutron capture therapy for malignant brain tumors.

Takagaki M, Ono K, Oda Y, Kikuchi H, Nemoto H, Iwamoto S, Cai J, Yamamoto Y.

Cancer Res. 1996 May 1;56(9):2017-20.

13.

Selective uptake of para-boronophenylalanine increases in amelanotic melanoma cells transfected by the tyrosinase gene.

Hiratsuka J, Kondoh H, Tsuboi T, Yoshino K, Imajo Y, Mishima Y.

Melanoma Res. 2000 Jun;10(3):297-302.

PMID:
10890385
14.

Experimental Studies of Boronophenylalanine ((10)BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment.

Carpano M, Perona M, Rodriguez C, Nievas S, Olivera M, Santa Cruz GA, Brandizzi D, Cabrini R, Pisarev M, Juvenal GJ, Dagrosa MA.

Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):344-52. doi: 10.1016/j.ijrobp.2015.05.039. Epub 2015 Jun 5.

PMID:
26232853
15.

Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: an experimental study that supports a potential new application of BNCT.

Monti Hughes A, Heber EM, Pozzi E, Nigg DW, Calzetta O, Blaumann H, Longhino J, Nievas SI, Aromando RF, Itoiz ME, Trivillin VA, Schwint AE.

Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S313-7. doi: 10.1016/j.apradiso.2009.03.070. Epub 2009 Mar 27.

PMID:
19376711
16.

The hamster cheek pouch as a model of oral cancer for boron neutron capture therapy studies: selective delivery of boron by boronophenylalanine.

Kreimann EL, Itoiz ME, Dagrosa A, Garavaglia R, Farías S, Batistoni D, Schwint AE.

Cancer Res. 2001 Dec 15;61(24):8775-81.

17.

Improvement of the tumor-suppressive effect of boron neutron capture therapy for amelanotic melanoma by intratumoral injection of the tyrosinase gene.

Morita N, Hiratsuka J, Kondoh H, Uno M, Asano T, Niki Y, Sakurai Y, Ono K, Harada T, Imajo Y.

Cancer Res. 2006 Apr 1;66(7):3747-53.

18.

Boron neutron capture therapy (BNCT) selectively destroys human clear cell sarcoma in mouse model.

Fujimoto T, Andoh T, Sudo T, Fujita I, Moritake H, Sugimoto T, Sakuma T, Akisue T, Kawabata S, Kirihata M, Suzuki M, Sakurai Y, Ono K, Fukumori Y, Kurosaka M, Ichikawa H.

Appl Radiat Isot. 2013 Mar;73:96-100. doi: 10.1016/j.apradiso.2012.12.001. Epub 2012 Dec 11.

PMID:
23306161
19.
20.

Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases.

Trivillin VA, Garabalino MA, Colombo LL, González SJ, Farías RO, Monti Hughes A, Pozzi EC, Bortolussi S, Altieri S, Itoiz ME, Aromando RF, Nigg DW, Schwint AE.

Appl Radiat Isot. 2014 Jun;88:94-8. doi: 10.1016/j.apradiso.2013.11.115. Epub 2013 Dec 5.

PMID:
24360862

Supplemental Content

Support Center